Clinical factors associated with achieving K/DOQI hemoglobin targets in hemodialysis patients

International Urology and Nephrology

Volumn 35, Issue 3, 2003, Pages 399-405

  Li, Suying ^a   Foley, Robert N ^a   Gilbertson, David T ^a   Liu, Jiannong ^a   Collins, Allan J ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Anemia; Dialysis; Epoetin; Hemoglobin; Iron

Indexed keywords

HEMOGLOBIN; IRON; RECOMBINANT ERYTHROPOIETIN; UREA; IRON DERIVATIVE;

ADULT; AGED; ANEMIA; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; DRUG RESPONSE; FEMALE; HEALTH CARE QUALITY; HEMODIALYSIS PATIENT; HUMAN; IRON THERAPY; KIDNEY DISEASE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PREVALENCE; RETROSPECTIVE STUDY; RISK ASSESSMENT; STATISTICAL ANALYSIS; TREATMENT OUTCOME; AGE; BLOOD; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; FOLLOW UP; HOSPITALIZATION; IRON DEFICIENCY ANEMIA; METHODOLOGY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PRACTICE GUIDELINE; QUALITY OF LIFE; RENAL REPLACEMENT THERAPY; RISK FACTOR; SEX DIFFERENCE; STANDARD; STATISTICAL MODEL; TOTAL QUALITY MANAGEMENT;

ADULT; AGE FACTORS; AGED; ANEMIA, HYPOCHROMIC; ERYTHROPOIETIN, RECOMBINANT; FEMALE; FOLLOW-UP STUDIES; GUIDELINES; HEMOGLOBINS; HUMANS; IRON COMPOUNDS; KIDNEY FAILURE, CHRONIC; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; QUALITY OF LIFE; RENAL DIALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SEX FACTORS; TOTAL QUALITY MANAGEMENT; TREATMENT OUTCOME;

EID: 3042806903     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:UROL.0000022951.17591.0b     Document Type: Article

References (16)

1. Rocco MV, Bedinger MR, Milam R et al. Duration of dialysis and its relationship to dialysis adequacy, anemia management, and serum albumin level. Am J Kidney Dis 2001; 38: 813-823.
2. McClellan WM, Frankenfield DL, Wish JB et al. End-Stage Renal Disease Core Indicators Work Group. Subcutaneous erythropoietin results in lower dose and equivalent hematocrit levels among adult hemodialysis patients: results from the 1998 End-Stage Renal Disease Core Indicators Project. Am J Kidney Dis 2001; 37: E36.
3. Ifudu O, Uribarri J, Rajwani I et al. Gender modulates responsiveness to recombinant erythropoietin. Am J Kidney Dis 2001; 38: 518-522.
4. Ifudu O, Feldman J, Friedman EA. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease. N Engl J Med 1996; 334: 420-425.
5. NKF-K/DOQI Clinical practice guidelines for anemia of chronic kidney disease: update 2000. Am J Kidney Dis 2001; 37: S182-S238.
6. U.S. Renal Data System. USRDS 2002 Annual Data Report. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2002.
7. 1 Annual Report. ESRD Clinical Performance Measures Project. Am J Kidney Dis 2002; 39: S4-S98.
8. Collins AJ, Li S, St. Peter WL et al. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol 2001; 12: 2465-2473.
9. Collins AJ, Li S, Ebben J et al. Hematocrit levels and associated Medicare expenditures. Am J Kidney Dis 2000; 36: 282-293.
10. Glicklich D, Kutcher R, Rosenblatt R et al. Time-related increase in hematocrit on chronic hemodialysis: uncertain role of renal cysts. Am J Kidney Dis 1990; 15: 46-54.
11. Kao HH, Chen KS, Tsai CJ et al. Clinical characteristic of parenteral iron supplementation in hemodialysis patients receiving erythropoietin therapy. Changgeng Yi Xue Za Zhi 2000; 23: 608-613.
12. Silverberg DS, Blum M, Agbaria Z et al. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period. Clin Nephrol 2001; 55: 212-219.
13. Fink J, Blahut S, Reddy M et al. Use of erythropoietin before the initiation of dialysis and its impact on mortality. Am J Kidney Dis 2001; 37: 348-355.
14. Hayashi T, Suzuki A, Shoji T et al. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis 2000; 35: 250-256.
15. Collins AJ, Ma JZ, Xia H et al. Trends in anemia treatment with erythropoietin usage and patient outcomes. Am J Kidney Dis 1998; 32(6, Suppl. 4): S133-S141.
16. Davis D, Charles PJ, Potter A et al. Anaemia of chronic disease in rheumatoid arthritis: in vivo effects of tumour necrosis factor alpha blockade. Br J Rheumatol 1997; 36: 950-956.